康辰药业
(603590)
| 流通市值：84.73亿 | | | 总市值：85.77亿 |
| 流通股本：1.57亿 | | | 总股本：1.59亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 366,314,713.38 | 212,131,620.11 | 189,977,701.84 | 307,759,615.46 |
| 交易性金融资产 | 391,050,361.08 | 390,849,333.32 | 450,662,375.93 | 332,555,610.34 |
| 应收票据及应收账款 | 345,252,441.13 | 302,722,762.67 | 251,013,321.48 | 289,160,633.42 |
| 应收账款 | 345,252,441.13 | 302,722,762.67 | 251,013,321.48 | 289,160,633.42 |
| 应收款项融资 | 4,275,154.97 | 4,328,518.6 | 6,363,288 | 5,720,828.48 |
| 预付款项 | 11,889,335.14 | 9,745,892.9 | 4,712,451.02 | 28,771,043.44 |
| 其他应收款合计 | 32,803,577.54 | 33,796,598 | 33,841,304.86 | 34,391,717.72 |
| 存货 | 69,521,027.12 | 69,870,047.21 | 72,383,172.34 | 60,894,611.23 |
| 其他流动资产 | 156,443,276.99 | 168,930,402.25 | 77,586,421.58 | 75,360,368.27 |
| 流动资产合计 | 1,377,549,887.35 | 1,192,375,175.06 | 1,086,540,037.05 | 1,134,614,428.36 |
| 非流动资产: | | | | |
| 长期股权投资 | 48,610,808.32 | 49,141,244.08 | 49,322,264.29 | 49,170,120.57 |
| 其他权益工具投资 | 696,604,008.15 | 703,359,892.89 | 748,399,124.49 | 740,514,803.77 |
| 其他非流动金融资产 | 88,253,178.36 | 88,083,749.01 | 88,804,516.55 | 74,323,507 |
| 固定资产 | 191,098,987 | 193,589,225.97 | 199,173,514.04 | 205,001,305.39 |
| 在建工程 | 216,114,155.24 | 217,857,179.85 | 209,845,880.18 | 209,105,161.76 |
| 生产性生物资产 | 362,500 | 400,000 | 437,500 | - |
| 使用权资产 | 12,536,449.42 | 15,531,822.78 | 17,275,950.94 | 19,020,079.09 |
| 无形资产 | 838,008,635.73 | 840,040,613.57 | 842,667,929.51 | 848,022,890.3 |
| 开发支出 | 263,629,184.63 | 248,557,598.83 | 233,770,135.29 | 194,885,624.65 |
| 商誉 | - | - | - | 97,642,801.5 |
| 长期待摊费用 | 495,378.32 | 547,669.74 | 587,961.17 | 640,877.59 |
| 递延所得税资产 | 21,806,951.78 | 24,766,826.49 | 27,465,038.74 | 21,043,408.33 |
| 其他非流动资产 | 116,745,575.43 | 310,917,356.75 | 415,399,038.2 | 402,071,309.8 |
| 非流动资产合计 | 2,494,265,812.38 | 2,692,793,179.96 | 2,833,148,853.4 | 2,861,441,889.75 |
| 资产总计 | 3,871,815,699.73 | 3,885,168,355.02 | 3,919,688,890.45 | 3,996,056,318.11 |
| 流动负债: | | | | |
| 短期借款 | 182,390,695.81 | 159,739,719.5 | 140,955,196.27 | 103,045,986.7 |
| 应付票据及应付账款 | 51,592,173.07 | 51,283,103.87 | 73,569,212.75 | 98,437,923.84 |
| 应付账款 | 51,592,173.07 | 51,283,103.87 | 73,569,212.75 | 98,437,923.84 |
| 合同负债 | 2,354,059.34 | 3,325,933.91 | 6,426,596.76 | 2,191,802.84 |
| 应付职工薪酬 | 27,962,295.98 | 20,939,151.53 | 43,685,764.1 | 23,740,119.54 |
| 应交税费 | 11,977,452.28 | 7,124,639.31 | 8,880,929.21 | 7,755,065.87 |
| 其他应付款合计 | 48,075,538.8 | 62,192,968.43 | 71,082,843.44 | 68,089,436.42 |
| 一年内到期的非流动负债 | 9,123,866.99 | 8,138,084.09 | 8,071,679.09 | 16,185,194.97 |
| 其他流动负债 | 47,380.12 | 21,561.17 | 10,993.64 | 25,339.86 |
| 流动负债合计 | 333,523,462.39 | 312,765,161.81 | 352,683,215.26 | 319,470,870.04 |
| 非流动负债: | | | | |
| 长期借款 | 55,574,712 | 49,576,409 | 49,845,809 | 85,451,506 |
| 租赁负债 | 6,564,008 | 8,980,667.34 | 10,800,404.42 | 12,551,921.2 |
| 递延收益 | 38,623,037.9 | 39,549,246.51 | 40,475,455.14 | 20,706,963.76 |
| 递延所得税负债 | 31,718,308.21 | 34,632,686.75 | 39,720,009.87 | 40,461,525.14 |
| 非流动负债合计 | 132,480,066.11 | 132,739,009.6 | 140,841,678.43 | 159,171,916.1 |
| 负债合计 | 466,003,528.5 | 445,504,171.41 | 493,524,893.69 | 478,642,786.14 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 159,356,477 | 159,356,477 | 159,356,477 | 160,000,000 |
| 资本公积 | 950,547,293.83 | 948,240,986.8 | 944,595,003.46 | 959,952,197.71 |
| 减:库存股 | 19,192,990 | 35,927,570 | 35,927,570 | 55,923,616.53 |
| 其他综合收益 | -12,230,834.16 | -6,488,332.13 | 31,795,014.73 | 25,093,342.11 |
| 盈余公积 | 80,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 未分配利润 | 1,960,291,997.3 | 2,009,090,794.28 | 1,964,593,400.48 | 2,035,305,885.97 |
| 归属于母公司股东权益合计 | 3,118,771,943.97 | 3,154,272,355.95 | 3,144,412,325.67 | 3,204,427,809.26 |
| 少数股东权益 | 287,040,227.26 | 285,391,827.66 | 281,751,671.09 | 312,985,722.71 |
| 股东权益合计 | 3,405,812,171.23 | 3,439,664,183.61 | 3,426,163,996.76 | 3,517,413,531.97 |
| 负债和股东权益合计 | 3,871,815,699.73 | 3,885,168,355.02 | 3,919,688,890.45 | 3,996,056,318.11 |
| 公告日期 | 2025-08-28 | 2025-04-26 | 2025-04-26 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |